drugset / Trial / NCT02802137

24-hour Efficacy and Ocular Surface With Talfuprost and Triple Combined Therapy

NCT02802137

Phase 4 Completed 43 enrolled Aristotle University Of Thessaloniki
RandomizedCrossoverSingle-blindTreatment

Summary

The study investigated the 24-hour efficacy and ocular surface health with preservative-free tafluprost and a combined preservative-free regimen (tafluprost and dorzolamide/timolol fixed combination) in open-angle glaucoma patients insufficiently controlled on latanoprost monotherapy and showing signs, or symptoms of ocular surface disease with preservative-containing latanoprost monotherapy. This trial randomized open-angle glaucoma patients insufficiently controlled (IOP \> 20 mm Hg) on branded, or generic latanoprost monotherapy who required further IOP reduction and who demonstrated clinical signs, or symptoms of ocular surface disease.

Timeline

Start
2015-03
Primary completion
2015-12
Completion
2016-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator Dorzolamide Small molecule Topical
Comparator Tafluprost Other / unclassified Topical
Comparator Timolol Other / unclassified Topical